for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

44.26EUR

Change

-0.68(-1.51%)

Volume

4,169,355

Today's Range

44.01

 - 

45.20

52 Week Range

44.01

 - 

57.73

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
44.94
Open
45.06
Volume
4,169,355
3M AVG Volume
58.77
Today's High
45.20
Today's Low
44.01
52 Week High
57.73
52 Week Low
44.01
Shares Out (MIL)
982.42
Market Cap (MIL)
43,477.18
Forward P/E
7.10
Dividend (Yield %)
4.52

Next Event

Bayer AG at Berenberg European Conference

Latest Developments

更多

Bayer Invests EUR 100 Mln In Sustainable Health Products

Bayer And Microsoft Enter Into Strategic Partnership

Bayer Starts Study With Finerenon In Children With Chronic Kidney Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non

Industry

Major Drugs

Contact Info

Kaiser-Wilhelm-Allee 1

51373

Germany

+49.214.301

https://www.bayer.de/

Executive Leadership

Norbert Winkeljohann

Chairman of the Supervisory Board

Werner Baumann

Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

Independent Vice Chairman of the Supervisory Board

Wolfgang U. Nickl

Chief Financial Officer, Member of the Management Board

Liam Condon

Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit

Key Stats

2.17 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

39.6K

2019

43.5K

2020

41.4K

2021(E)

43.2K
EPS (EUR)

2018

5.940

2019

6.400

2020

6.390

2021(E)

6.235
Price To Earnings (TTM)
192.76
Price To Sales (TTM)
1.01
Price To Book (MRQ)
1.40
Price To Cash Flow (TTM)
10.10
Total Debt To Equity (MRQ)
134.28
LT Debt To Equity (MRQ)
118.88
Return on Investment (TTM)
0.28
Return on Equity (TTM)
0.20

Latest News

Latest News

UPDATE 1-Bayer's Nubeqa drug improves survival in prostate cancer trial

* Nubeqa is one of three potential blockbuster drug candidates (Adds background on Bayer pipeline, Nubeqa market)

UPDATE 1-Elanco Animal Health to cut 380 jobs globally

Elanco Animal Health Inc kicked off another round of layoffs on Tuesday, saying it would cut 380 positions globally as a part of a restructuring started after its $6.89 billion purchase of Bayer's veterinary drugs unit last year.

UPDATE 1-Jury orders Bayer to pay $62 mln over contaminated U.S. school building

A U.S. jury on Wednesday ordered Bayer AG to pay $62 million to students and others who say they were exposed to toxic chemicals made by the company's predecessor, Monsanto Co, in a school building in Washington state.

Jury orders Bayer to pay $62 mln over contaminated school building

A jury on Wednesday ordered Bayer AG to pay $62 million to students and others who say they were exposed to toxic chemicals made by the company's predecessor, Monsanto Co, in a school building in Washington state.

Bayer says head of agriculture unit quits

Bayer said on Tuesday the head of its crop science unit, Liam Condon, would quit at the end of the year to pursue other career opportunities, following disappointing results earlier this year.

U.S. farm co-op CHS to pay members to enroll in Bayer carbon farming program

Agricultural seeds and chemicals supplier Bayer AG is expanding its carbon farming program to members of U.S. farm cooperative CHS Inc, boosting incentives for members to participate in the program, the companies said on Wednesday.

Bayer wins EU patent extension for best-selling Xarelto drug

Bayer on Friday said the European Patent Office had maintained the company's patent for its best-selling stroke prevention pill Xarelto (rivaroxaban), extending the patent's expiry date by almost two years.

UPDATE 2-Bayer: farmers pre-buying crop inputs as supply-chain snarls continue

U.S. farmers are pre-buying seeds and chemicals they need earlier than normal, in a bid to secure supplies for next spring amid sector-wide supply-chain problems, a top executive at German agricultural and pharmaceuticals firm Bayer AG said on Tuesday.

Bayer, CureVac terminate COVID-19 shot production partnership

Bayer AG has terminated a vaccine manufacturing partnership under which it would have helped produce CureVac's COVID-19 shot, a spokesperson for Bayer told a German newspaper.

UPDATE 2-Bayer blasts 'unscientific' rejection by Mexican regulator of GMO corn permit

Bayer is evaluating its legal options after Mexican health regulators for the first time rejected a GMO corn permit it was seeking, the German pharmaceutical and crop science giant said in a statement to Reuters on Friday, blasting the decision as "unscientific."

FOCUS-Corteva faces slow start as it takes aim at Bayer's Brazil soy reign

U.S. pesticide and seed maker Corteva Inc will take up to three times longer to break into Brazil's genetically modified soy seed market than it did in the United States, where Corteva's sales grew rapidly in recent years, the company said.

Bayer shares up after first trial win over Roundup

Shares in Bayer AG rose 2.5% in pre-market trade on Wednesday after the German agricultural and pharmaceuticals firm won its first trial over claims its Roundup weedkiller causes cancer.

Bayer wins its first Roundup jury verdict in case of child's cancer

Bayer AG won its first trial over claims its Roundup weedkiller causes cancer after a California jury found that the herbicide was not a substantial cause of a child's rare form of non-Hodgkin's lymphoma, the company said on Tuesday.

Bayer recalls some lots of Lotrimin, Tinactin antifungal sprays

Bayer said on Friday it was recalling some lots of Lotrimin AF and Tinactin antifungal spray products, due to the presence of benzene in some samples.

UPDATE 1-Bayer takes legal battle over Roundup cancer claims to U.S. Supreme Court

Bayer, trying to contain billions of dollars in legal costs, filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the German group's glyphosate-based weedkillers.

UPDATE 1-Soy growers criticise Brazil antitrust ruling on Bayer biotech seed JV

Brazilian soybean producers' group Aprosoja, representing 240,000 farmers, on Tuesday criticized federal antitrust agency CADE's decision to clear a joint venture formed by rivals Bayer AG, Corteva and Syngenta.

Soy growers criticise Brazil antitrust ruling on Bayer biotech seed JV

Brazilian soybean producers' group Aprosoja, representing 240,000 farmers, on Tuesday criticized federal antitrust agency CADE's decision to clear a joint venture formed by rivals Bayer AG, Corteva and Syngenta.

Bayer loses third appeals case over glyphosate weedkiller

Bayer lost a third appeal against U.S. court verdicts that awarded damages to customers blaming their cancers on use of its glyphosate-based weedkillers, leaving the German drugs and pesticides group to pin hopes for legal relief on the U.S. Supreme Court.

UPDATE 3-Bayer Q2 misses forecasts as costs, forex effects bite

* Shares down as much as 6.1% (Recasts, adds share reaction, comment)

UPDATE 3-Bayer to book extra $4.5 bln provision for Roundup litigation

Bayer said on Thursday it would book an additional provision of $4.5 billion related to litigation which alleges that its weedkiller Roundup can cause cancer.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up